OBJECTIVE: The aim was to evaluate published data contributing to the following areas: (1) FeNO as a predictive biomarker of response to biologic treatment; (2) the influence of biologic treatment in FeNO values; (3) FeNO as a biomarker for the prediction of exacerbations in patients treated with biologics.
METHODS: The systematic search was conducted on the Medline database through the Pubmed search engine, including all studies from 2009 to the present.
RESULTS: Higher baseline values of FeNO are associated with better clinical control in patients treated with omalizumab, dupilumab, and tezepelumab. FeNO dynamics during biologic treatment highlights a clear reduction in FeNO values in patients treated with anti-IL4/13 and anti-IL13, as well as in patients treated with tezepelumab. During the treatment, FeNO may help to predict clinical worsening and to differentiate eosinophilic from non-eosinophilic exacerbations.
CONCLUSIONS: Higher baseline FeNO levels appear to be associated with a greater benefit in terms of clinical control and reduction of exacerbation rate, while FeNO dynamics during biologic treatment remains a largely unexplored issue since few studies have investigated it as a primary outcome. FeNO remains detectable during biologic treatment, but its potential utility as a biomarker of clinical control is still unclear and represents an interesting research area to be developed.
目的:目的是评估已发表的有助于以下领域的数据:(1)FeNO作为生物治疗反应的预测生物标志物;(2)生物治疗对FeNO值的影响;(3)FeNO作为生物标志物用于预测使用生物制剂治疗的患者的恶化。
方法:通过Pubmed搜索引擎在Medline数据库上进行了系统搜索,
结果:在接受奥马珠单抗治疗的患者中,较高的FeNO基线值与更好的临床控制相关,
结论:较高的基线FeNO水平似乎在临床控制和降低加重率方面具有更大的益处。